Skip to main content

Table 3 Exposure to rituximab during the study for all patients

From: Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

  Infusion 1 Infusion 2 Infusion 3 Infusion 4
Received infusion 351a 341a 290b 278
Infusion at the faster rate NA 337 289 278
Completed 1000 mgc 338 333 288 277
Total infusion hours
  n 338 333 288 277
  Mean (SD) 4.4 (0.3) 2.0 (0.1) 2.1 (0.3) 2.0 (0.1)
  Range 4.1-6.4 1.8-3.2 1.9-4.3 1.9-2.4
  > 2.5 h 338 (100%) 5 (1.5%) 12 (4.2%) 0
  > 4.5 h 41 (12.1%) 0 0 0
  1. NA, not applicable; SD, standard deviation. aInfusion rate and dose could not be determined for 4 patients because the site failed to record the infusion volume. Of these 4 patients, 3 at Day 168 and 2 at Day 182 received rituximab at the faster rate. bRituximab was administered at the standard infusion rate in 1 patient. cRituximab dose was derived from the sum of the volume received at each segment. To account for truncation errors, the derived dose of 970 mg or larger was considered as completed 1000 mg.